Proactive Investors - Run By Investors For Investors

ANGLE’s Parsortix to be in focus at AACC annual meeting

Parsortix will be in focus of experts later today at the AACC meeting.
blood vials
Parsortix can capture cancer cells in blood for analysis.

ANGLE PLC’s (OTCMKTS:ANPCY, LON:AGL) Parsortix device will be the focus of a poster presentation at the American Association for Clinical Chemistry (AACC) annual meeting later today.

Posters are used at large conventions such as the AACC to showcase discoveries or developments.

In the case of ANGLE it will be used to demonstrate Parsortix’s ability to harvest breast cancer cells for subsequent gene expression analysis.

The presentation is based around the pioneering work of James Reuben, a professor at the University of Texas MD Anderson Cancer Center.

According to ANGLE chief technology officer, Shane Booth, gene expression analysis could prove a “very important” new diagnostic tool.

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use